4D Molecular Therapeutics Inc.

37.69-2.89-7.12%Vol 133.49K1Y Perf -5.78%
Apr 9th, 2021 16:00 DELAYED
BID37.68 ASK37.69
Open40.55 Previous Close40.58
Pre-Market- After-Market-
 - -  - -%
Target Price
60.00 
Analyst Rating
— — 0.00
Potential %
59.19 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap1.01B 
Earnings Rating
Price Range Ratio 52W %
17.48 
Earnings Date
-

Today's Price Range

37.5640.68

52W Range

34.0055.11

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Neutral
Performance
1 Week
-5.87%
1 Month
-26.66%
3 Months
-
6 Months
-
1 Year
-5.78%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
FDMT37.69-2.8900-7.12
AAPL132.992.63002.02
GOOG2 285.8820.44000.90
MSFT255.852.60001.03
XOM55.87-0.1300-0.23
WFC40.500.47001.17
JNJ161.25-1.7200-1.06
FB312.46-0.5600-0.18
GE13.600.15001.12
JPM156.281.16000.75
Earnings HistoryEstimateReportedSurprise %
----
----
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume133.49K
Shares Outstanding26.69M
Trades Count2.01K
Dollar Volume5.83M
Avg. Volume162.87K
Avg. Weekly Volume67.67K
Avg. Monthly Volume205.93K
Avg. Quarterly Volume163.27K

4D Molecular Therapeutics Inc. (NASDAQ: FDMT) stock closed at 37.69 per share at the end of the most recent trading day (a -7.12% change compared to the prior day closing price) with a volume of 133.49K shares and market capitalization of 1.01B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 78 people. 4D Molecular Therapeutics Inc. CEO is David Kirn.

The one-year performance of 4D Molecular Therapeutics Inc. stock is -5.78%, while year-to-date (YTD) performance is %. FDMT stock has a five-year performance of %. Its 52-week range is between 34 and 55.11, which gives FDMT stock a 52-week price range ratio of 17.48%

4D Molecular Therapeutics Inc. currently has a PE ratio of -4.90, a price-to-book (PB) ratio of 4.52, a price-to-sale (PS) ratio of 81.17, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -32.72%, a ROC of -75.01% and a ROE of -61.82%. The company’s profit margin is -%, its EBITDA margin is -307.70%, and its revenue ttm is $13.61 Million , which makes it $0.51 revenue per share.

Of the last four earnings reports from 4D Molecular Therapeutics Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. 4D Molecular Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for 4D Molecular Therapeutics Inc. is (), with a target price of $, which is 0.00% compared to the current price. The earnings rating for 4D Molecular Therapeutics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

4D Molecular Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

4D Molecular Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ATR14 : 2.30, Money Flow Index : 48.89, ROC : 10.53, RSI : 55.01, STOCH (14,3) : 93.03, STOCH RSI : 1.00, Williams %R : -6.97), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of 4D Molecular Therapeutics Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
0
0
0
Moderate Buy
0
0
0
Hold
0
0
0
Moderate Sell
0
0
0
Strong Sell
0
0
0
Summary Rating---

4D Molecular Therapeutics Inc.

4D Molecular Therapeutics Inc is a development stage precision gene therapy company. It engages in developing a broad pipeline of transformative gene therapy product candidates designed to treat patients suffering from lysosomal storage diseases, lung diseases, muscular dystrophies, and ophthalmic diseases. The AAV vectors are designed to provide targeted delivery by routine clinical routes, efficient transduction, reduced immunogenicity and resistance to pre-existing antibodies which enable to develop gene therapies.

CEO: David Kirn

Telephone: +1 510 505-2680

Address: 5858 Horton Street, Emeryville 94608, CA, US

Number of employees: 78

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

50%50%

News

Stocktwits